Vice President, Clinical DevelopmentNeurocrine Biosciences, Inc.San Diego, California, United States
Disclosure information not submitted.
SAT-465 - Long-Term Crinecerfont Treatment Reduced ACTH and 17-Hydroxyprogesterone and Improved Clinical Outcomes in Children and Adolescents with Classic Congenital Adrenal Hyperplasia: 2-Year Results from Cahtalyst™ Pediatric
Saturday, June 13, 20269:30 AM - 4:30 PM CT
SUN-465 - Long-Term Crinecerfont Enables Sustained Decreases in Glucocorticoid Doses and Improves Clinical Outcomes in Children and Adolescents with Classic Congenital Adrenal Hyperplasia: 2-Year Results from Cahtalyst™ Pediatric
Sunday, June 14, 20269:00 AM - 4:00 PM CT
SUN-467 - A Cross-Sectional Survey on Crinecerfont and Quality of Life of Adults with Classic Congenital Adrenal Hyperplasia (CAH) in the United States (US) Participating in Cahtalyst Adult Open-Label Extension (OLE) Study
.jpg)
.jpg)